Research map: Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer

Back to the article

Papers in this map

  1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer · Herbert I. Hurwitz · 2004 · 11034 citations · Cited by this paper
  2. mRNA Vaccines for Influenza: Hope for a Universal Vaccine? · 2026 · Related
  3. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer · Alan Sandler · 2006 · 5800 citations · Cited by this paper
  4. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · 2025 · Related
  5. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer · Napoleone Ferrara · 2004 · 2634 citations · Cited by this paper
  6. Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential · 2025 · Related
  7. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. · A. Hilary Calvert · 1989 · 1884 citations · Cited by this paper
  8. Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics · 2026 · Related
  9. PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM · Lars Lindbom · 2005 · 1139 citations · Cited by this paper
  10. Interleukin-23 Inhibitors in Inflammatory Bowel Disease · 2026 · Related
  11. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer · Melody Cobleigh · 2003 · 489 citations · Cited by this paper
  12. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline · 2025 · Related
  13. Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics · Thi Huyen Tram Nguyen · 2016 · 405 citations · Cited by this paper
  14. Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry · 2026 · Related
  15. Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation · EFPIA MID3 Workgroup · 2015 · 373 citations · Cited by this paper
  16. Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review · 2025 · Related
  17. Biosimilars: what clinicians should know · Martina Weise · 2012 · 362 citations · Cited by this paper
  18. Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study · 2025 · Related
  19. Clinical pharmacokinetics of bevacizumab in patients with solid tumors · Jianfeng Lü · 2008 · 348 citations · Cited by this paper
  20. Assessment of Actual Significance Levels for Covariate Effects in NONMEM · Ulrika Wählby · 2001 · 291 citations · Cited by this paper
  21. Extensions to the Visual Predictive Check to facilitate model performance evaluation · Teun M. Post · 2008 · 206 citations · Cited by this paper
  22. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential · Andrew W. Mulcahy · 2017 · 206 citations · Cited by this paper
  23. Population pharmacokinetics of bevacizumab in cancer patients with external validation · Kelong Han · 2016 · 75 citations · Cited by this paper
  24. Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity · Jia Kang · 2020 · 28 citations · Cited by this paper
  25. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males · Sang‐Heon Cho · 2019 · 24 citations · Cited by this paper
  26. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer · Cheryl S. W. Li · 2019 · 14 citations · Cited by this paper
  27. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial · Claire F. Verschraegen · 2022 · 12 citations · Cited by this paper
  28. Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging? · Morgane Philipp · 2024 · 6 citations · Cited by this paper
  29. Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer · Joel S. Owen · 2023 · 3 citations · Cited by this paper
  30. Exposure–response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab · Suemin Park · 2024 · 3 citations · Cited by this paper
  31. Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer · Q. Hong · 2026 · 2 citations · Cited by this paper
  32. 2016 Peer Reviewers, The Journal of Clinical Pharmacology · 2017 · 1 citation · Cited by this paper
  33. Untitled · Cited by this paper

Source: OpenAlex (CC0)